Press "Enter" to skip to content

RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC – Cancer Therapy Advisor

admin 0

RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC  Cancer Therapy Advisor

One year after publishing phase Ib results of the RELAY trial, investigators presented phase 3 findings at the 2019 American Society of Clinical Oncology …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *